KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Ratio (2016 - 2025)

Fulgent Genetics' Equity Ratio history spans 10 years, with the latest figure at 0.92 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 1.0% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, down 1.0%, while the annual FY2025 figure was 0.92, 1.0% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.92 at Fulgent Genetics, down from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.93 in Q2 2023 and bottomed at 0.8 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.92 (2022), against an average of 0.91.
  • The largest YoY upside for Equity Ratio was 14.69% in 2021 against a maximum downside of 11.93% in 2021.
  • A 5-year view of Equity Ratio shows it stood at 0.91 in 2021, then grew by 0.49% to 0.92 in 2022, then rose by 0.13% to 0.92 in 2023, then increased by 0.89% to 0.93 in 2024, then fell by 1.0% to 0.92 in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Equity Ratio are 0.92 (Q4 2025), 0.92 (Q3 2025), and 0.93 (Q2 2025).